期刊文献+

青蒿素对实验性糖尿病大鼠肾脏PDGF-B表达上调的影响 被引量:8

Effect of Artemisinin on the upregulation of PDGF-B protein expression in the kidney of experimental diabetic rats
下载PDF
导出
摘要 目的探讨青蒿素对实验性糖尿病大鼠肾脏血小板衍化生长因子-B(PDGF-B)表达上调的抑制作用。方法将36只雄性SD大鼠随机分为正常对照组(A组)、糖尿病非治疗组(B组)及糖尿病青蒿素治疗组(C组),B、C组采用腹腔单剂量注射链脲佐菌素(STZ)65 mg/kg建立糖尿病大鼠模型。C组给予青蒿素300 g/(kg·d)腹腔注射。于实验第3周、第6周各组分别宰杀6只大鼠,采用免疫组织化学染色法检测肾皮质PDGF-B的蛋白表达。并检测肌酐清除率(Ccr)、24 h尿白蛋白排泄率(UAER)及肾质量/体质量。肾组织制备电子显微镜切片以观察肾组织超微结构改变。结果 C组大鼠肾质量/体质量、Ccr、UAER均显著低于B组(P<0.05或0.01)。免疫组化染色发现B组大鼠肾组织PDGF-B表达显著上调(P<0.01),C组表达明显下调(P<0.01)。电镜示B组大鼠肾脏病变广泛,肾小球系膜细胞增生,系膜区增宽,基底膜增厚,脏层细胞肥大。C组大鼠肾脏超微结构异常显著减轻。结论青蒿素能减轻糖尿病大鼠肾脏病变,主要通过下调糖尿病大鼠肾组织PDGF-B表达来实现。 Objective It is to investigate the inhibitory effect of artemisinin on the upregulation of PDGF - B protein ex- pression in the kidney of experimental diabetic rats. Methods 36 male SD rats were randomly divided into normal control group (A group), non-treatment diabetic group (B group), and diabetic treated with Artemisinin group (C group). The diabetic models of rats were established by STZ 65 mg/kg by intraperitoneal injection in group B and group C. Group C was given Arte- misinin 300 g/( kg ~ d) by intraperitoneal injection. UAER, Ccr as well as the profile of kidney hypertrophy were observed af- ter 3, 6 weeks of treatment, while PDGF -B protein expression was measured by immunohistological staining. In addition, re- nal tissues were observed by transmission electron microscopy. Results Kidney/body weight ratio, Ccr, and UAER of the rats in group C were significantly lower than those in group B (P 〈 0.05 or 0.01 ). Immumohistochemical staining results showed that the protein expression of PDGF - B (P 〈 0. O1 ) significantly increased in renal tissue in group B ( P 〈 0.01 ) , while de- creased in group C( P 〈 O. 01 ). Electron microscopy results showed that in the rats of group B, extensive kidney lesion, glo- merular mesangial cell proliferation and mesangial area broadening, thickening of basement membrane, dirty layer cell hyper- trophy were found, while in groupC, abnormal uhrastructure was significantly relieved. Conclusion Atemisinin can relieve re- nal lesions in experimental diabetic rats, which was partly through inhibiting PDGF- B expression in renal cortices.
出处 《现代中西医结合杂志》 CAS 2014年第13期1392-1393,1396,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 糖尿病肾病 青蒿素 血小板衍化生长因子-B 免疫组织化学 Atemisinin diabetic nephropathy platelet-derived growth factor - B immunohistological staining
  • 相关文献

参考文献6

  • 1陈颖颖,丁峰.肾素-血管紧张素系统阻断剂在慢性肾病治疗中的应用[J].上海医药,2013,34(1):5-9. 被引量:12
  • 2Persson DL,Jin L,Xuan H ,et al. Effects of aliskiren on blood pres- sure, aibuminuria, and (pro)rennin receptor expression in diabetic TG (mRen-2) 27 rats[J]. Hypertension, 2008,52(1):130 - 136.
  • 3Chow FY, Nikolic-Paterson DJ, Atkins RC, et al. Macro, phages in streptozotoein-induced diabetic nephropathy: potential role in renal fibrosis [ J ] - Tesch GH Nephrol Dial Transplant, 2004,19 : 2987 - 2996.
  • 4Fraser D, Brunskill N,Ito T,et al. Long-term exposure of proximal tubular epithelial cells to glucose induces transforming growth factor- beta 1 synthesis via an autoerine PDGF loop [ J l. Am J Pathol, 2003,163:2565 - 2574.
  • 5Langham RG, Kelly DJ, Maguire J, et al. Over-expression of plate- let-derived growth factor in human diabetic nephropathy[ J]. Neph- rol Dial Transplant,2003,18 : 1392 - 1396.
  • 6Kang JH, Chae YM, Park KK, et al. Suppression of mesangial cell proliferation and extraceltular matrix production in streptozotocin-in- duced diabetic rats by Spl decoy oligodeoxynucleotide in vitro and in vivo[J]. J Cell Biochem,2008,103:663-674.

二级参考文献16

  • 1侯凡凡,谢迪.慢性肾脏病应用肾素-血管紧张素系统阻断剂的治疗目标[J].中华高血压杂志,2007,15(z1):32-34. 被引量:13
  • 2李晓东,郭志军,高山林,赵慧娟,张林霞,孙东立.醛固酮及其受体拮抗剂对肾小球系膜细胞转化生长因子β1基因表达的影响[J].中国现代医学杂志,2006,16(13):1937-1940. 被引量:7
  • 3李建飞,温黎青,赵勤,吴小宁,王芳芳,陈廷波.醛固酮受体拮抗剂对慢性肾脏病蛋白尿的影响[J].中国医学工程,2007,15(5):413-415. 被引量:5
  • 4MacKinnon M, Shurraw S, Akbari A, et al. Combination therapy with an angiotensin receptor blockers and an ACE inhibitor in proteinuria renal disease: a systematic review of the efficacy and safety data [J]. Am J Kidney Dis, 2006, 48(1): 8-20.
  • 5Retraction - Combination treatment of angiotensin-Ⅱ receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomized controlled trial [J]. Lancet, 2009, 374(9697): 1226.
  • 6Mann JE Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTAGET study): a multicentre, randomized, double- blind, controlled trial [J]. Lancet, 2008, 372(9638): 547-553.
  • 7Allard J, Buleon M, Cellier E, et al. ACE inhibitor reduces growth factor expression and signaling but also albuminuria through β2-kinin glomerular receptor activation in diabetic rats [J]. Am J physiol Renal Physiol, 2007, 293(4): F1083- F1092.
  • 8De Silva L, Weir MR. Renin inhibitor and microalbuminuria development meaningful predictor of kidney disease progression [J]. Curr Opin Nephrol Hypertens, 2010, 19(5): 437-443.
  • 9Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective rennin inhibitor, provides anti-hypertensive efficacy alone and in combination with valsartan [J]. Am J Hypertens, 2007, 20(1): 11-20.
  • 10Zheng Z, Shi H, Jia J, et al. A systematic review and meta-analysis of aliskiren and angiotension receptor blockers in the management of essential hypertension [J]. J Renin Angiotensin Aldosterone Syst, 2011, 12(2): 102-112.

共引文献11

同被引文献173

引证文献8

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部